{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:05:13Z","timestamp":1774343113181,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00347-011-2452-4","type":"journal-article","created":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T12:25:35Z","timestamp":1329481535000},"page":"112-120","source":"Crossref","is-referenced-by-count":3,"title":["Pharmakologische Ans\u00e4tze in der Therapie erblicher Netzhautdegenerationen","Pharmacological concepts to treat hereditary retinal degenerations"],"prefix":"10.1007","volume":"109","author":[{"given":"C.M.","family":"Poloschek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"J\u00e4gle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,19]]},"reference":[{"key":"2452_CR1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0039-6257(84)90233-9","volume":"28","author":"Yanoff","year":"1984","unstructured":"Yanoff M, Fine BS, Brucker AJ, Eagle RC Jr (1984) Pathology of human cystoid macular edema. Surv Ophthalmol 28 (Suppl):505\u2013511","journal-title":"Surv Ophthalmol"},{"key":"2452_CR2","doi-asserted-by":"crossref","unstructured":"Walia S, Fishman GA, Hajali M (2009) Prevalence of cystic macular lesions in patients with Usher II syndrome. Eye (Lond) 23(5):1206\u20131209","DOI":"10.1038\/eye.2008.105"},{"key":"2452_CR3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/archopht.1977.04450050076006","volume":"95","author":"Fishman","year":"1977","unstructured":"Fishman GA, Fishman M, Maggiano J (1977) Macular lesions associated with retinitis pigmentosa. Arch Ophthalmol 95(5):798\u2013803","journal-title":"Arch Ophthalmol"},{"key":"2452_CR4","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/archophthalmol.2010.172","volume":"128","author":"Genead","year":"2010","unstructured":"Genead MA, Fishman GA (2010) Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and Usher syndrome. Arch Ophthalmol 128(9):1146\u20131150","journal-title":"Arch Ophthalmol"},{"key":"2452_CR5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/humu.21096","volume":"30","author":"Schorderet","year":"2009","unstructured":"Schorderet DF, Escher P (2009) NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP). Hum Mutat 30(11):1475\u20131485","journal-title":"Hum Mutat"},{"key":"2452_CR6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archopht.1988.01060140350030","volume":"106","author":"Cox","year":"1988","unstructured":"Cox SN, Hay E, Bird AC (1988) Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 106(9):1190\u20131195","journal-title":"Arch Ophthalmol"},{"key":"2452_CR7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archopht.1989.01070020519031","volume":"107","author":"Fishman","year":"1989","unstructured":"Fishman GA, Gilbert LD, Fiscella RG et al (1989) Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 107(10):1445\u20131452","journal-title":"Arch Ophthalmol"},{"key":"2452_CR8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138161208783877884","volume":"14","author":"Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases-an overview. Curr Pharm Des 14(7):603\u2013614","journal-title":"Curr Pharm Des"},{"key":"2452_CR9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/IAE.0b013e31805f6b79","volume":"27","author":"Apushkin","year":"2007","unstructured":"Apushkin MA, Fishman GA, Grover S, Janowicz MJ (2007) Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina 27(8):1112\u20131118","journal-title":"Retina"},{"key":"2452_CR10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/IAE.0b013e3181e587f9","volume":"31","author":"Thobani","year":"2011","unstructured":"Thobani A, Fishman GA (2011) The use of carbonic anhydrase inhibitors in the retreatment of cystic macular lesions in retinitis pigmentosa and X-linked retinoschisis. Retina 31(2):312\u2013315","journal-title":"Retina"},{"key":"2452_CR11","first-page":"269","volume":"34","author":"Greenstein","year":"1993","unstructured":"Greenstein VC, Holopigian K, Siderides E et al (1993) The effects of acetazolamide on visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci 34(1):269\u2013273","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2452_CR12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00006982-199705000-00009","volume":"17","author":"Grover","year":"1997","unstructured":"Grover S, Fishman GA, Fiscella RG, Adelman AE (1997) Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina 17(3):222\u2013231","journal-title":"Retina"},{"key":"2452_CR13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2005.12.030","volume":"141","author":"Grover","year":"2006","unstructured":"Grover S, Apushkin MA, Fishman GA (2006) Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 141(5):850\u2013858","journal-title":"Am J Ophthalmol"},{"key":"2452_CR14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/bjo.2006.107466","volume":"91","author":"Fishman","year":"2007","unstructured":"Fishman GA, Apushkin MA (2007) Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 91(6):743\u2013745","journal-title":"Br J Ophthalmol"},{"key":"2452_CR15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archophthalmol.2009.398","volume":"128","author":"Genead","year":"2010","unstructured":"Genead MA, Fishman GA, Walia S (2010) Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol 128(2):190\u2013197","journal-title":"Arch Ophthalmol"},{"key":"2452_CR16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-0420.2005.00395.x","volume":"83","author":"Ozdemir","year":"2005","unstructured":"Ozdemir H, Karacorlu M, Karacorlu S (2005) Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 83(2):248\u2013251","journal-title":"Acta Ophthalmol Scand"},{"key":"2452_CR17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/archopht.125.6.759","volume":"125","author":"Scorolli","year":"2007","unstructured":"Scorolli L, Morara M, Meduri A et al (2007) Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 125(6):759\u2013764","journal-title":"Arch Ophthalmol"},{"key":"2452_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/02713680802710692","volume":"34","author":"Yuzbasioglu","year":"2009","unstructured":"Yuzbasioglu E, Artunay O, Rasier R et al (2009) Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. Curr Eye Res 34(3):231\u2013237","journal-title":"Curr Eye Res"},{"key":"2452_CR19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0420.2006.00872.x","volume":"85","author":"Melo","year":"2007","unstructured":"Melo GB, Farah ME, Aggio FB (2007) Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand 85(4):461\u2013463","journal-title":"Acta Ophthalmol Scand"},{"key":"2452_CR20","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00417-011-1629-5","volume":"249","author":"Bohm","year":"2011","unstructured":"Bohm MR, Uhlig CE (2011) Use of intravitreal triamcinolone and bevacizumab in Coats\u2018 disease with central macular edema. Graefes Arch Clin Exp Ophthalmol 249(7):1099\u20131101","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2452_CR21","doi-asserted-by":"crossref","unstructured":"Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010. pii: 479364","DOI":"10.1155\/2010\/479364"},{"key":"2452_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bjo.2009.175356","volume":"95","author":"Clemson","year":"2010","unstructured":"Clemson CM, Tzekov R, Krebs M et al (2010) Therapeutic potential of valproic acid for retinitis pigmentosa. Br J Ophthalmol 95(1):89\u201393","journal-title":"Br J Ophthalmol"},{"key":"2452_CR23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/bjo.2010.198176","volume":"95","author":"Sandberg","year":"2010","unstructured":"Sandberg MA, Rosner B, Weigel-DiFranco C, Berson EL (2010) Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. Br J Ophthalmol 95(5):744","journal-title":"Br J Ophthalmol"},{"key":"2452_CR24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/bjo.2010.194373","volume":"95","author":"Schooneveld","year":"2010","unstructured":"Schooneveld MJ van, Born LI van den, Genderen M van, Bollemeijer JG (2010) The conclusions of Clemson et al concerning valproic acid are premature. Br J Ophthalmol 95(1):153, author reply 153\u2013154","journal-title":"Br J Ophthalmol"},{"key":"2452_CR25","unstructured":"AKF PR (2011) Warnhinweis zu Valproins\u00e4ure bei RP \u2013 Anforderungen an den Nachweis von erw\u00fcnschten Medikamentenwirkungen. http:\/\/www.pro-retina.de\/forschungsf\u00f6rderung\/wissenschaftliche-beratungsgremien\/empfehlungen\/warnhinweis-zu-valproins\u00e4ure-bei. (Zugegriffen: 17.07.2011)"},{"key":"2452_CR26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1073\/pnas.40.10.1014","volume":"40","author":"Cohen","year":"1954","unstructured":"Cohen S, Levi-Montalcini R, Hamburger V (1954) A nerve growth-stimulating factor isolated from sarcom as 37 and 180. Proc Natl Acad Sci U S A 40(10):1014\u20131018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2452_CR27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00006982-200512001-00009","volume":"25","author":"Lavail","year":"2005","unstructured":"Lavail MM (2005) Survival factors for treatment of retinal degenerative disorders: preclinical gains and issues for translation into clinical studies. Retina 25(8 Suppl):25\u201326","journal-title":"Retina"},{"key":"2452_CR28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14712598.6.7.717","volume":"6","author":"Tao","year":"2006","unstructured":"Tao W (2006) Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 6(7):717\u2013726","journal-title":"Expert Opin Biol Ther"},{"key":"2452_CR29","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1073\/pnas.0600236103","volume":"103","author":"Sieving","year":"2006","unstructured":"Sieving PA, Caruso RC, Tao W et al (2006) Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 103(10):3896\u20133901","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2452_CR30","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1167\/iovs.10-6479","volume":"52","author":"Talcott","year":"2011","unstructured":"Talcott KE, Ratnam K, Sundquist SM et al (2011) Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci 52(5):2219\u20132226","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2452_CR31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000320500","volume":"225","author":"Nakazawa","year":"2011","unstructured":"Nakazawa M, Ohguro H, Takeuchi K et al (2011) Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. Ophthalmologica 225(2):120\u2013126","journal-title":"Ophthalmologica"},{"key":"2452_CR32","first-page":"3","volume":"40","author":"Seeliger","year":"1999","unstructured":"Seeliger MW, Biesalski HK, Wissinger B et al (1999) Phenotype in retinol deficiency due to a hereditary defect in retinol binding protein synthesis. Invest Ophthalmol Vis Sci 40(1):3\u201311","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2452_CR33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archopht.1993.01090060049022","volume":"111","author":"Berson","year":"1993","unstructured":"Berson EL, Rosner B, Sandberg MA et al (1993) A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 111(6):761\u2013772","journal-title":"Arch Ophthalmol"},{"key":"2452_CR34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/archophthalmol.2010.32","volume":"128","author":"Berson","year":"2010","unstructured":"Berson EL, Rosner B, Sandberg MA et al (2010) Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 128(4):403\u2013411","journal-title":"Arch Ophthalmol"},{"key":"2452_CR35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archopht.122.9.1297","volume":"122","author":"Berson","year":"2004","unstructured":"Berson EL, Rosner B, Sandberg MA et al (2004) Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 122(9):1297\u20131305","journal-title":"Arch Ophthalmol"},{"key":"2452_CR36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3129\/i10-028","volume":"45","author":"Lee","year":"2010","unstructured":"Lee TK, Clandinin MT, Hebert M, MacDonald IM (2010) Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial. Can J Ophthalmol 45(5):514\u2013519","journal-title":"Can J Ophthalmol"},{"key":"2452_CR37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/OPTH.S10049","volume":"4","author":"Querques","year":"2010","unstructured":"Querques G, Benlian P, Chanu B et al (2010) DHA supplementation for late onset Stargardt disease: NAT-3 study. Clin Ophthalmol 4:575\u2013580","journal-title":"Clin Ophthalmol"},{"key":"2452_CR38","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1073\/pnas.041606498","volume":"98","author":"Sieving","year":"2001","unstructured":"Sieving PA, Chaudhry P, Kondo M et al (2001) Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. Proc Natl Acad Sci U S A 98(4):1835\u20131840","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2452_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200932010-00001","volume":"32","author":"Laties","year":"2009","unstructured":"Laties AM (2009) Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf 32(1):1\u201318","journal-title":"Drug Saf"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-011-2452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-011-2452-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-011-2452-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T22:14:54Z","timestamp":1561328094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-011-2452-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["2452"],"URL":"https:\/\/doi.org\/10.1007\/s00347-011-2452-4","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}